These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19052001)

  • 1. Gene therapy offers HD patients relief from some symptoms. Tetrabenazine inhibits the transport of a molecule called vesicular monoamine transporter type 2 or VMAT2.
    Morrow T
    Manag Care; 2008 Nov; 17(11):46-7. PubMed ID: 19052001
    [No Abstract]   [Full Text] [Related]  

  • 2. Deutetrabenazine for the treatment of Huntington's chorea.
    Bashir H; Jankovic J
    Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
    Chen JJ; Ondo WG; Dashtipour K; Swope DM
    Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrabenazine (Xenazine) for Huntington's chorea.
    Med Lett Drugs Ther; 2009 Jan; 51(1304):7-8. PubMed ID: 19172140
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
    Stahl SM
    CNS Spectr; 2018 Aug; 23(4):239-247. PubMed ID: 30160230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The psychopharmacology of Huntington disease.
    Petersén Å; Weydt P
    Handb Clin Neurol; 2019; 165():179-189. PubMed ID: 31727211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.
    Ugolev Y; Segal T; Yaffe D; Gros Y; Schuldiner S
    J Biol Chem; 2013 Nov; 288(45):32160-32171. PubMed ID: 24062308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of weight gain in treatments for Tourette syndrome: tetrabenazine versus neuroleptic drugs.
    Ondo WG; Jong D; Davis A
    J Child Neurol; 2008 Apr; 23(4):435-7. PubMed ID: 18192650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Jankovic J
    Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
    Guay DR
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):331-73. PubMed ID: 20869622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetrabenazine.
    Hayden MR; Leavitt BR; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2009 Jan; 8(1):17-8. PubMed ID: 19116624
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacological properties and clinical efficacy of tetrabenazine (Choreazine(®)Tablets 12.5 mg), a therapeutic agent for non-rhythmic involuntary movement].
    Machida K; Kawakami D; Miki M
    Nihon Yakurigaku Zasshi; 2014 Mar; 143(3):144-51. PubMed ID: 24614638
    [No Abstract]   [Full Text] [Related]  

  • 13. The long-term effect of tetrabenazine in the management of Huntington disease.
    Fasano A; Cadeddu F; Guidubaldi A; Piano C; Soleti F; Zinzi P; Bentivoglio AR
    Clin Neuropharmacol; 2008; 31(6):313-8. PubMed ID: 19050408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease.
    Frank S; Ondo W; Fahn S; Hunter C; Oakes D; Plumb S; Marshall F; Shoulson I; Eberly S; Walker F; Factor S; Hunt V; Shinaman A; Jankovic J
    Clin Neuropharmacol; 2008; 31(3):127-33. PubMed ID: 18520979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating depression and suicidality in tetrabenazine users with Huntington disease.
    Schultz JL; Killoran A; Nopoulos PC; Chabal CC; Moser DJ; Kamholz JA
    Neurology; 2018 Jul; 91(3):e202-e207. PubMed ID: 29925548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tetrabenazine (tetrabenazine Orphan) orally].
    J Pharm Belg; 2014 Dec; (4):49-50. PubMed ID: 25562927
    [No Abstract]   [Full Text] [Related]  

  • 17. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.
    Dean M; Sung VW
    Drug Des Devel Ther; 2018; 12():313-319. PubMed ID: 29497277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic use of tetrabenazine].
    López Del Val LJ; López-García E; Martínez-Martínez L; Santos-Lasaosa S
    Rev Neurol; 2009 May 16-31; 48(10):523-33. PubMed ID: 19434587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine.
    Raffo A; Hancock K; Polito T; Xie Y; Andan G; Witkowski P; Hardy M; Barba P; Ferrara C; Maffei A; Freeby M; Goland R; Leibel RL; Sweet IR; Harris PE
    J Endocrinol; 2008 Jul; 198(1):41-9. PubMed ID: 18577569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease.
    Heo YA; Scott LJ
    Drugs; 2017 Nov; 77(17):1857-1864. PubMed ID: 29080203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.